Advertisement
Singapore markets close in 5 hours 30 minutes
  • Straits Times Index

    3,419.68
    -20.20 (-0.59%)
     
  • Nikkei

    41,051.49
    +137.84 (+0.34%)
     
  • Hang Seng

    17,817.58
    -210.70 (-1.17%)
     
  • FTSE 100

    8,241.26
    +70.14 (+0.86%)
     
  • Bitcoin USD

    55,330.23
    -3,580.01 (-6.08%)
     
  • CMC Crypto 200

    1,149.83
    -111.35 (-8.84%)
     
  • S&P 500

    5,537.02
    +28.01 (+0.51%)
     
  • Dow

    39,308.00
    -23.90 (-0.06%)
     
  • Nasdaq

    18,188.30
    +159.54 (+0.88%)
     
  • Gold

    2,369.40
    0.00 (0.00%)
     
  • Crude Oil

    83.65
    -0.23 (-0.27%)
     
  • 10-Yr Bond

    4.3550
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,614.92
    -1.83 (-0.11%)
     
  • Jakarta Composite Index

    7,266.20
    +45.31 (+0.63%)
     
  • PSE Index

    6,543.42
    +35.93 (+0.55%)
     

Altimmune to Participate at Leerink Partners Therapeutics Forum

Altimmune, Inc
Altimmune, Inc

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as meetings between participating companies and investors.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

ADVERTISEMENT

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com